Canine Mammary Tumors: Classification, Biomarkers, Traditional and Personalized Therapies.
Natalia NosalovaMykhailo HuniadiĽubica HorňákováAlexandra Agyagosová-ValenčákováSlavomir HorňákKamil NagoosJuraj VozarDaša ČížkováPublished in: International journal of molecular sciences (2024)
In recent years, many studies have focused their attention on the dog as a proper animal model for human cancer. In dogs, mammary tumors develop spontaneously, involving a complex interplay between tumor cells and the immune system and revealing several molecular and clinical similarities to human breast cancer. In this review, we summarized the major features of canine mammary tumor, risk factors, and the most important biomarkers used for diagnosis and treatment. Traditional therapy of mammary tumors in dogs includes surgery, which is the first choice, followed by chemotherapy, radiotherapy, or hormonal therapy. However, these therapeutic strategies may not always be sufficient on their own; advancements in understanding cancer mechanisms and the development of innovative treatments offer hope for improved outcomes for oncologic patients. There is still a growing interest in the use of personalized medicine, which should play an irreplaceable role in the research not only in human cancer therapy, but also in veterinary oncology. Moreover, immunotherapy may represent a novel and promising therapeutic option in canine mammary cancers. The study of novel therapeutic approaches is essential for future research in both human and veterinary oncology.
Keyphrases
- endothelial cells
- risk factors
- induced pluripotent stem cells
- pluripotent stem cells
- end stage renal disease
- cancer therapy
- palliative care
- papillary thyroid
- machine learning
- minimally invasive
- stem cells
- prostate cancer
- squamous cell carcinoma
- early stage
- type diabetes
- ejection fraction
- chronic kidney disease
- metabolic syndrome
- young adults
- acute coronary syndrome
- coronary artery disease
- peritoneal dialysis
- bone marrow
- percutaneous coronary intervention
- cell therapy
- childhood cancer
- patient reported
- insulin resistance